

## Datasheet: HCA215

<b>Description:</b>	HUMAN ANTI INFLIXIMAB
<b>Specificity:</b>	INFLIXIMAB
<b>Other names:</b>	Remicade®
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD19370_hlgG1
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Product Form</b>	Human IgG1 antibody (lambda light chain) selected from the HuCAL phage display library and expressed in a human cell line.
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A.
<b>Source</b>	HKB-11
<b>Buffer Solution</b>	Phosphate buffered saline.
<b>Preservative Stabilisers</b>	0.09% Sodium Azide (NaN <sub>3</sub> )
<b>Approx. Protein Concentrations</b>	Antibody concentration 0.5 mg/ml.
<b>Immunogen</b>	Infliximab.

**Specificity** **Human anti Infliximab, clone AbD19370\_hlgG1**, is an anti-idiotypic antibody that specifically recognizes free infliximab monoclonal antibody and infliximab when bound to its target, Tumor Necrosis Factor Alpha (TNF $\alpha$ ). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Human anti Infliximab, clone AbD19370\_hlgG1 is not paratope-specific and is non-inhibitory; it binds to an epitope outside the infliximab binding site. This epitope is shared with other chimeric antibodies that are highly homologous to infliximab including the chimeric antibody cetuximab, but not rituximab. The antibody can be used as a detection antibody in a pharmacokinetic (PK) assay in the bridging format to measure total drug (free, partially bound and fully bound). As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

Infliximab (branded as Remicade®) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. It is directed against TNF $\alpha$  and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNF $\alpha$  expressing T-lymphocytes.

[View a summary of all anti-infliximab antibodies.](#)

---

**Affinity** The monovalent intrinsic affinity of this antibody was measured as  $K_D=1.4$  nM by real time, label-free molecular interaction analysis on immobilized infliximab.

---

**ELISA** This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with [HCA212](#) as the capture reagent.  
Protocol: [PK bridging ELISA to measure total drug](#)  
Protocol: [ADA bridging ELISA](#)

---

**Storage** This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

---

**Guarantee** 12 months from date of despatch.

---

**Acknowledgements** This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See [bio-rad.com/en-us/trademarks](http://bio-rad.com/en-us/trademarks) for details.  
Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.

---

**Health And Safety** Material Safety Datasheet documentation #10040 available at:

**Information** <https://www.bio-rad-antibodies.com/SDS/HCA215>  
10040

---

**Licensed Use** For *in vitro*. research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

---

**Regulatory** For research purposes only.

---

**Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

---

## Related Products

### Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)  
[RECOMBINANT HUMAN TNF ALPHA \(PHP051\)](#)  
[HUMAN ANTI INFILIXIMAB \(HCA212\)](#)  
[MOUSE ANTI HUMAN IgG \(Fc\) CH2 DOMAIN:HRP \(MCA647P\)](#)  
[HISPEC ASSAY DILUENT \(BUF049A\)](#)

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)  
'M420927:230706'

Printed on 12 Aug 2023

---

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)